Neuronetics, Inc.
Neuronetics, Inc. develops and commercializes NeuroStar Advanced Therapy System, a non-invasive medical device used in psychiatric care, along with recurring treatment-session access codes and related services. The company is based in the United States and sells primarily to psychiatrists and psychiatric practices, with a small international distribution footprint.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaCapital equipment sales, rentals, upgrades, and related hardware for the NeuroStar platform.
Recurring access codes and treatment-session revenue used with the NeuroStar system.
Revenue from treatments performed in company-operated or affiliated clinic settings.
Service, repair, research collaboration, and extended warranty revenue.
Tuotteet
Raportoitu · osuus liikevaihdosta- Services58,3 %
- Products41,7 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
Neuronetics sells to psychiatrists, group psychiatric practices, and treatment centers that use NeuroStar to treat patients with major depressive disorder. Its revenue also depends on third-party payors, including Medicare, managed care plans, and commercial insurers, because patient reimbursement supports treatment adoption and utilization.
Buy NeuroStar systems and treatment-session access to treat MDD patients in-office and generate recurring patient revenue.
Operate treatment sites and earn clinic revenue from performed sessions and patient fees.
Medicare, managed care, and commercial insurers reimburse treatments and influence utilization.
Purchase and distribute products in select non-U.S. markets.
Strategia
Neuronetics is focused on expanding adoption of NeuroStar through direct sales coverage, customer support, and clinical evidence that supports additional indications. It also emphasizes growing recurring revenue from treatment sessions and clinic operations, while relying on outsourced manufacturing and distributor channels for parts of its operating model.
More systems in the field and higher session volume increase recurring revenue opportunities.
Broader clinical use can expand the addressable market and support adoption.
Clinic operations add a direct patient-fee stream and deepen market penetration.
Maantiede
The business is overwhelmingly U.S.-centric, with the United States accounting for 98% of revenue in the nine months ended September 30, 2025. International sales are limited and are handled through independent distributors in a few select markets outside the U.S.
Riskit
Neuronetics depends on reimbursement, physician adoption, and patient willingness to pursue treatment, so demand can be sensitive to payor policy and macro conditions. The company also faces execution risk from outsourced manufacturing, product concentration around NeuroStar, and financial covenant/liquidity pressure associated with its capital structure.
- Reimbursement and payor policy riskVaikutus: KorkeaTodennäköisyys: Korkea
Clinic and treatment-session demand depend on Medicare, managed care, and commercial coverage.
Kohdistuu: U.S. psychiatric treatment reimbursement
- Liquidity and covenant riskVaikutus: KorkeaTodennäköisyys: Korkea
Borrowings under the Perceptive Facility include revenue and liquidity covenants.
Kohdistuu: Debt compliance and financing flexibility
- Manufacturing and supply chain riskVaikutus: KorkeaTodennäköisyys: Matala
Components are produced by third-party contract manufacturers and assembled through outsourced partners.
Kohdistuu - Product concentration riskVaikutus: Korkea
The business is centered on NeuroStar and related treatment-session revenue.
Kohdistuu: Single-platform dependence
- Macroeconomic demand sensitivityVaikutus: KeskitasoTodennäköisyys: Korkea
Patients may delay or forego medical services during weaker economic conditions.
Kohdistuu: Consumer and provider spending on psychiatric care
Kirjanpito
Harkinnanvaraiset erätRevenue is recognized using expected-value estimates for contractual allowances and discounts.
Vaikutus: Can materially affect reported revenue and receivables
Payor fee schedules and concessions can change the amount ultimately recognized.
Vaikutus: Creates estimation uncertainty in clinic revenue
System sales, treatment sessions, clinic revenue, and other services are recognized differently.
Vaikutus: Affects revenue mix and comparability across periods
Extended warranty and repair obligations may require deferral or accruals.
Vaikutus: Influences deferred revenue and service-cost estimates
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
NeuroPace Inc
NPCE · Surgical & Medical Instruments & Apparatus
NeuroPace is a U.S.-based medical device company focused on epilepsy treatment through its implantable RNS System.
Enveric Biosciences, Inc.
ENVB · Pharmaceutical Preparations
Neuraxis, INC
NRXS · Electromedical & Electrotherapeutic Apparatus
Neuraxis, INC is a U.S.-based medical device company focused on neuromodulation therapies for pediatric and adult patients.
ClearPoint Neuro, Inc.
CLPT · Surgical & Medical Instruments & Apparatus
NRX Pharmaceuticals, Inc.
NRXP · Pharmaceutical Preparations
Neurogene Inc.
NGNE · Pharmaceutical Preparations
Päivitetty: 24.9.2026